{"pmid":32405120,"pmcid":"PMC7217793","title":"The contribution of diabetic micro-angiopathy to adverse outcomes in COVID-19.","text":["The contribution of diabetic micro-angiopathy to adverse outcomes in COVID-19.","Increasing evidence points to endothelial cell dysfunction as a key pathophysiological factor in severe coronavirus disease-19 (COVID-19), manifested by platelet aggregation, microthrombi and altered vasomotor tone. This may be driven by direct endothelial cell entry by the virus, or indirectly by activated inflammatory cascade. Major risk groups identified for adverse outcomes in COVID-19 are diabetes, and those from the Black, Asian and ethnic minority (BAME) populations. Hyperglycaemia (expressed as glycated haemoglobin or mean hospital glucose) correlates with worse outcomes in COVID-19. It is not known whether hyperglycaemia is causative or is a surrogate marker - persistent hyperglycaemia is well known as an aetiological agent in microangiopathy. In this article, we propose that pre-existing endothelial dysfunction of microangiopathy, more commonly evident in diabetes and BAME groups, makes an individual vulnerable to the subsequent 'endothelitis' of COVID-19 infection.","Diabetes Res Clin Pract","Whyte, Martin B","Vas, Prashanth","Heiss, Christian","Feher, Michael D","32405120"],"abstract":["Increasing evidence points to endothelial cell dysfunction as a key pathophysiological factor in severe coronavirus disease-19 (COVID-19), manifested by platelet aggregation, microthrombi and altered vasomotor tone. This may be driven by direct endothelial cell entry by the virus, or indirectly by activated inflammatory cascade. Major risk groups identified for adverse outcomes in COVID-19 are diabetes, and those from the Black, Asian and ethnic minority (BAME) populations. Hyperglycaemia (expressed as glycated haemoglobin or mean hospital glucose) correlates with worse outcomes in COVID-19. It is not known whether hyperglycaemia is causative or is a surrogate marker - persistent hyperglycaemia is well known as an aetiological agent in microangiopathy. In this article, we propose that pre-existing endothelial dysfunction of microangiopathy, more commonly evident in diabetes and BAME groups, makes an individual vulnerable to the subsequent 'endothelitis' of COVID-19 infection."],"journal":"Diabetes Res Clin Pract","authors":["Whyte, Martin B","Vas, Prashanth","Heiss, Christian","Feher, Michael D"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405120","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.diabres.2020.108217","e_drugs":["Glucose"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666802845517611008,"score":9.490897,"similar":[{"pmid":32451317,"title":"The contribution of diabetic micro-angiopathy to adverse outcomes in COVID-19.","text":["The contribution of diabetic micro-angiopathy to adverse outcomes in COVID-19.","Increasing evidence points to endothelial cell dysfunction as a key pathophysiological factor in severe coronavirus disease-19 (COVID-19), manifested by platelet aggregation, microthrombi and altered vasomotor tone. This may be driven by direct endothelial cell entry by the virus, or indirectly by activated inflammatory cascade. Major risk groups identified for adverse outcomes in COVID-19 are diabetes, and those from the Black, Asian and ethnic minority (BAME) populations. Hyperglycaemia (expressed as glycated haemoglobin or mean hospital glucose) correlates with worse outcomes in COVID-19. It is not known whether hyperglycaemia is causative or is a surrogate marker - persistent hyperglycaemia is well known as an aetiological agent in microangiopathy. In this article, we propose that pre-existing endothelial dysfunction of microangiopathy, more commonly evident in diabetes and BAME groups, makes an individual vulnerable to the subsequent 'endothelitis' of COVID-19 infection.","Diabetes Res Clin Pract","Whyte, Martin B","Vas, Prashanth","Heiss, Christian","Feher, Michael D","32451317"],"abstract":["Increasing evidence points to endothelial cell dysfunction as a key pathophysiological factor in severe coronavirus disease-19 (COVID-19), manifested by platelet aggregation, microthrombi and altered vasomotor tone. This may be driven by direct endothelial cell entry by the virus, or indirectly by activated inflammatory cascade. Major risk groups identified for adverse outcomes in COVID-19 are diabetes, and those from the Black, Asian and ethnic minority (BAME) populations. Hyperglycaemia (expressed as glycated haemoglobin or mean hospital glucose) correlates with worse outcomes in COVID-19. It is not known whether hyperglycaemia is causative or is a surrogate marker - persistent hyperglycaemia is well known as an aetiological agent in microangiopathy. In this article, we propose that pre-existing endothelial dysfunction of microangiopathy, more commonly evident in diabetes and BAME groups, makes an individual vulnerable to the subsequent 'endothelitis' of COVID-19 infection."],"journal":"Diabetes Res Clin Pract","authors":["Whyte, Martin B","Vas, Prashanth","Heiss, Christian","Feher, Michael D"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32451317","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.diabres.2020.108217","e_drugs":["Glucose"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667881798492749825,"score":1318.7788},{"pmid":32447101,"title":"Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports.","text":["Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports.","Diabetes mellitus is challenging in the context of the COVID-19 pandemic. The prevalence of diabetes patients hospitalized in intensive care units for COVID-19 is two- to threefold higher, and the mortality rate at least double, than that of non-diabetes patients. As the population with diabetes is highly heterogeneous, it is of major interest to determine the risk factors of progression to a more serious life-threatening COVID-19 infection. This brief review discusses the main findings of CORONADO, a prospective observational study in France that specifically addressed this issue as well as related observations from other countries, mainly China and the US. Some prognostic factors beyond old age have been identified: for example, an increased body mass index is a major risk factor for requiring respiratory assistance. Indeed, obesity combines several risk factors, including impaired respiratory mechanics, the presence of other comorbidities and inappropriate inflammatory responses, partly due to ectopic fat deposits. While previous diabetic microvascular (renal) and macrovascular complications also increase risk of death, the quality of past glucose control had no independent influence on hospitalized diabetes patient outcomes, and whether the quality of glucose control might modulate risk of COVID-19 in non-hospitalized diabetes patients is still unknown. In addition, no negative signs regarding the use of RAAS blockers and DPP-4 inhibitors and outcomes of COVID-19 could be identified. Hyperglycaemia at the time of hospital admission is associated with poor outcomes, but it may simply be considered a marker of severity of the infection. Thus, the impact of glucose control during hospitalization on outcomes related to COVID-19, which was not investigated in the CORONADO study, is certainly deserving of specific investigation.","Diabetes Metab","Scheen, Andre J","Marre, Michel","Thivolet, Charles","32447101"],"abstract":["Diabetes mellitus is challenging in the context of the COVID-19 pandemic. The prevalence of diabetes patients hospitalized in intensive care units for COVID-19 is two- to threefold higher, and the mortality rate at least double, than that of non-diabetes patients. As the population with diabetes is highly heterogeneous, it is of major interest to determine the risk factors of progression to a more serious life-threatening COVID-19 infection. This brief review discusses the main findings of CORONADO, a prospective observational study in France that specifically addressed this issue as well as related observations from other countries, mainly China and the US. Some prognostic factors beyond old age have been identified: for example, an increased body mass index is a major risk factor for requiring respiratory assistance. Indeed, obesity combines several risk factors, including impaired respiratory mechanics, the presence of other comorbidities and inappropriate inflammatory responses, partly due to ectopic fat deposits. While previous diabetic microvascular (renal) and macrovascular complications also increase risk of death, the quality of past glucose control had no independent influence on hospitalized diabetes patient outcomes, and whether the quality of glucose control might modulate risk of COVID-19 in non-hospitalized diabetes patients is still unknown. In addition, no negative signs regarding the use of RAAS blockers and DPP-4 inhibitors and outcomes of COVID-19 could be identified. Hyperglycaemia at the time of hospital admission is associated with poor outcomes, but it may simply be considered a marker of severity of the infection. Thus, the impact of glucose control during hospitalization on outcomes related to COVID-19, which was not investigated in the CORONADO study, is certainly deserving of specific investigation."],"journal":"Diabetes Metab","authors":["Scheen, Andre J","Marre, Michel","Thivolet, Charles"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447101","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.diabet.2020.05.008","keywords":["diabetic complications","glucose control","mechanical ventilation","mortality","obesity","sars-cov-2"],"locations":["France","China","US"],"countries":["France","United States","China"],"countries_codes":["FRA|France","USA|United States","CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667698385913643010,"score":187.37106},{"pmid":32405783,"title":"Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.","text":["Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.","The coronavirus disease 2019 (COVID-19) pandemic has emerged as one of the greatest challenges faced by humankind in the recent past. People with diabetes and related comorbidities are at increased risk of its complications and of COVID-19-related death. Older age, multi-morbidity, hyperglycaemia, cardiac injury and severe inflammatory response are predictors of poor outcome. The complex interplay between COVID-19, diabetes and the effects of related therapies is being explored. Most patients experience a mild illness with COVID-19, while people with diabetes are at increased risk of severe disease. Optimising glycaemic control and adopting measures to prevent disease spread are critical aspects. The management of mild disease is supportive, while very many immunomodulatory and antiviral therapies are being investigated for the treatment of severe disease. Several of these agents have specific considerations for use in people with diabetes. Since mass population lockdowns are considered a key step in controlling disease spread, it follows that, in addition to the direct vulnerability to severe COVID-19, people with diabetes can be affected by limited access to healthcare, insulin, other medications and blood glucose monitoring equipment. Measures to prevent disease spread at the individual and community level are the key to mitigating the rapidly escalating pandemic, while agents for chemoprophylaxis and vaccines are being explored. People with diabetes should be recognised as a vulnerable group for complicated disease and are at risk during times of disturbed social systems. Strategies are needed to safeguard the health of patients with diabetes during the pandemic. This review summarises the current knowledge and perceived challenges for prevention and management of COVID-19 in people with diabetes.","Diabetologia","Katulanda, Prasad","Dissanayake, Harsha A","Ranathunga, Ishara","Ratnasamy, Vithiya","Wijewickrama, Piyumi S A","Yogendranathan, Nilukshana","Gamage, Kavinga K K","de Silva, Nipun L","Sumanatilleke, Manilka","Somasundaram, Noel P","Matthews, David R","32405783"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic has emerged as one of the greatest challenges faced by humankind in the recent past. People with diabetes and related comorbidities are at increased risk of its complications and of COVID-19-related death. Older age, multi-morbidity, hyperglycaemia, cardiac injury and severe inflammatory response are predictors of poor outcome. The complex interplay between COVID-19, diabetes and the effects of related therapies is being explored. Most patients experience a mild illness with COVID-19, while people with diabetes are at increased risk of severe disease. Optimising glycaemic control and adopting measures to prevent disease spread are critical aspects. The management of mild disease is supportive, while very many immunomodulatory and antiviral therapies are being investigated for the treatment of severe disease. Several of these agents have specific considerations for use in people with diabetes. Since mass population lockdowns are considered a key step in controlling disease spread, it follows that, in addition to the direct vulnerability to severe COVID-19, people with diabetes can be affected by limited access to healthcare, insulin, other medications and blood glucose monitoring equipment. Measures to prevent disease spread at the individual and community level are the key to mitigating the rapidly escalating pandemic, while agents for chemoprophylaxis and vaccines are being explored. People with diabetes should be recognised as a vulnerable group for complicated disease and are at risk during times of disturbed social systems. Strategies are needed to safeguard the health of patients with diabetes during the pandemic. This review summarises the current knowledge and perceived challenges for prevention and management of COVID-19 in people with diabetes."],"journal":"Diabetologia","authors":["Katulanda, Prasad","Dissanayake, Harsha A","Ranathunga, Ishara","Ratnasamy, Vithiya","Wijewickrama, Piyumi S A","Yogendranathan, Nilukshana","Gamage, Kavinga K K","de Silva, Nipun L","Sumanatilleke, Manilka","Somasundaram, Noel P","Matthews, David R"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405783","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s00125-020-05164-x","keywords":["covid-19","coronavirus","diabetes","sars-cov-2"],"topics":["Prevention"],"weight":1,"_version_":1666802845436870656,"score":178.51672},{"pmid":32421882,"title":"Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic.","text":["Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic.","During the early stages of the COVID-19 pandemic, hospitals in London, the UK epicentre, reported an unusually high number of people presenting with COVID-19 disease developing diabetic ketoacidosis, hyperosmolar hyperglycaemic state, or a combination of both. Very high doses of insulin were often needed to manage the hyperglycaemia. It has been proposed that these metabolic disturbances may result from severe insulin resistance combined with decreased insulin secretion due to beta cell dysfunction.","Diabet Med","Rayman, G","Lumb, A","Kennon, B","Cottrell, C","Nagi, D","Page, E","Voigt, D","Courtney, H","Atkins, H","Platts, J","Higgins, K","Dhatariya, K","Patel, M","Narendran, P","Kar, P","Newland-Jones, P","Stewart, R","Burr, O","Thomas, S","32421882"],"abstract":["During the early stages of the COVID-19 pandemic, hospitals in London, the UK epicentre, reported an unusually high number of people presenting with COVID-19 disease developing diabetic ketoacidosis, hyperosmolar hyperglycaemic state, or a combination of both. Very high doses of insulin were often needed to manage the hyperglycaemia. It has been proposed that these metabolic disturbances may result from severe insulin resistance combined with decreased insulin secretion due to beta cell dysfunction."],"journal":"Diabet Med","authors":["Rayman, G","Lumb, A","Kennon, B","Cottrell, C","Nagi, D","Page, E","Voigt, D","Courtney, H","Atkins, H","Platts, J","Higgins, K","Dhatariya, K","Patel, M","Narendran, P","Kar, P","Newland-Jones, P","Stewart, R","Burr, O","Thomas, S"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32421882","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/dme.14328","locations":["London","GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1667159284520058880,"score":175.64424},{"pmid":32406594,"title":"The Clinical Characteristics and Outcomes of Diabetes Mellitus and Secondary Hyperglycaemia Patients with Coronavirus Disease 2019: a Single-center, Retrospective, Observational Study in Wuhan.","text":["The Clinical Characteristics and Outcomes of Diabetes Mellitus and Secondary Hyperglycaemia Patients with Coronavirus Disease 2019: a Single-center, Retrospective, Observational Study in Wuhan.","AIMS: Since the pandemic outbreak of COVID-19, limited information is available on diabetic patients with COVID-19. MATERIALS AND METHODS: We retrospectively analysed 166 COVID-19 patients at Tongji Hospital (Wuhan) from February 8 to March 21, 2020. Clinical characteristics and outcomes (as of April 4, 2020) were compared among control (group 1), secondary hyperglycaemia (group 2: no diabetes history, FPG levels >/=7.0 mmol/L once and HbA1c values <6.5%) and diabetic (group 3) patients. RESULTS: Compared to group 1, groups 2 and 3 had higher rates of leukocytosis, neutrophilia, lymphocytopenia, eosinopenia, and levels of sCRP, ferritin and d-dimer (P < 0.05 for all). Group 2 patients have higher levels of LDH, prevalence of liver dysfunction and increased IL-8 than those in group 1, a higher prevalence of increased IL-8 was found in group 2 than in group 3 (P < 0.05 for all). The proportions of critical patients in groups 2 and 3 were significantly higher compared to group 1 (38.1%, 32.8% vs. 9.5%, P < 0.05 for both). Groups 2 and 3 had significantly longer hospital stays than group 1, which was nearly one week longer. The composite outcomes risks were 5.47 (1.56-19.82) and 2.61 (0.86-7.88) times greater in group 2 and 3 than in group 1. CONCLUSIONS: Hyperglycemia in both diabetes and secondary hyperglycemia patients with COVID-19 may indicate poor prognoses. There were differences between secondary hyperglycemia and diabetes patients. We recommend that clinicians pay more attention to the blood glucose status of COVID-19 patients, even those not diagnosed with diabetes before admission.","Diabetes Obes Metab","Zhang, Yang","Li, Haichao","Zhang, Jian","Cao, Yedi","Zhao, Xue","Yu, Nan","Gao, Ying","Ma, Jing","Zhang, Hong","Zhang, Junqing","Guo, Xiaohui","Liu, Xinmin","32406594"],"abstract":["AIMS: Since the pandemic outbreak of COVID-19, limited information is available on diabetic patients with COVID-19. MATERIALS AND METHODS: We retrospectively analysed 166 COVID-19 patients at Tongji Hospital (Wuhan) from February 8 to March 21, 2020. Clinical characteristics and outcomes (as of April 4, 2020) were compared among control (group 1), secondary hyperglycaemia (group 2: no diabetes history, FPG levels >/=7.0 mmol/L once and HbA1c values <6.5%) and diabetic (group 3) patients. RESULTS: Compared to group 1, groups 2 and 3 had higher rates of leukocytosis, neutrophilia, lymphocytopenia, eosinopenia, and levels of sCRP, ferritin and d-dimer (P < 0.05 for all). Group 2 patients have higher levels of LDH, prevalence of liver dysfunction and increased IL-8 than those in group 1, a higher prevalence of increased IL-8 was found in group 2 than in group 3 (P < 0.05 for all). The proportions of critical patients in groups 2 and 3 were significantly higher compared to group 1 (38.1%, 32.8% vs. 9.5%, P < 0.05 for both). Groups 2 and 3 had significantly longer hospital stays than group 1, which was nearly one week longer. The composite outcomes risks were 5.47 (1.56-19.82) and 2.61 (0.86-7.88) times greater in group 2 and 3 than in group 1. CONCLUSIONS: Hyperglycemia in both diabetes and secondary hyperglycemia patients with COVID-19 may indicate poor prognoses. There were differences between secondary hyperglycemia and diabetes patients. We recommend that clinicians pay more attention to the blood glucose status of COVID-19 patients, even those not diagnosed with diabetes before admission."],"journal":"Diabetes Obes Metab","authors":["Zhang, Yang","Li, Haichao","Zhang, Jian","Cao, Yedi","Zhao, Xue","Yu, Nan","Gao, Ying","Ma, Jing","Zhang, Hong","Zhang, Junqing","Guo, Xiaohui","Liu, Xinmin"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32406594","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/dom.14086","locations":["Wuhan","neutrophilia","lymphocytopenia","eosinopenia","clinicians","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Glucose"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666802845296361474,"score":174.37035}]}